CUPERTINO, Calif., Oct. 13 /PRNewswire-FirstCall/ — DURECT Corporation
(Nasdaq: DRRX) announced today financial results for the three months ended
September 30, 2005.
DURECT’s net loss for the three months ended September 30, 2005 was $3.0
million or 6 cents per share, compared to a net loss of $7.3 million or 14
cents per share for the same period in 2004. DURECT’s results for the three
months ended September 30, 2005 included non-cash charges of $363,000 for the
amortization of intangible assets and stock-based compensation, compared to
$311,000 for the same period in 2004. Cash used in operating activities was
$1.1 million for the three months ended September 30, 2005, compared to $4.4
million for the same period in 2004.
“We had a productive third quarter and executed on our corporate
objectives. For our ORADUR(TM) sustained release oral gel-cap technology,
which is the basis for the Remoxy(TM) product candidate under development by
Pain Therapeutics, we announced that Pain Therapeutics has achieved positive
results in an initial Phase III study. The data from the first Phase III
clinical study for Remoxy reinforces our belief that our ORADUR technology is
maturing and has demonstrated a variety of benefits, including the potential
to reduce abuse when compared to current commercial long-acting dosage forms,
as well as sustained release capabilities. We also completed dosing of the
third and final cohort for our Phase II trial for our SABER-Bupivacaine
product candidate in Australia, which we believe has the potential to be a
significant advancement over the current commercial treatments for post-
surgical pain. We look forward to announcing the data from this third cohort
during an upcoming medical conference later this month,” stated James E.
Brown, DVM, President and CEO of DURECT.
Dr. Brown added, “We continue to make significant progress on our other
development programs, including our DURIN(TM)-based leuprolide program (the
Memryte(TM) implant) under development with Voyager Pharmaceuticals for the
treatment of Alzheimer’s disease. Voyager has completed an end of Phase II
meeting with the FDA and is currently recruiting patients for pivotal Phase
III clinical studies using Memryte as an adjunctive therapy with acetyl
cholinesterase inhibitors (ACIs) for the treatment of mild to moderate
Total revenues were $8.6 million for the three months ended September 30,
2005, compared with $3.4 million for the same period in 2004. Total
collaborative research and development and other revenues were $5.4 million
for the three months ended September 30, 2005, compared with $1.6 million for
the same period in 2004. The increase in total revenues was primarily
attributable to higher collaborative research and development revenue
recognized from our agreements with Endo Pharmaceuticals, Inc. (TRANSDUR-
sufentanil), Voyager Pharmaceutical Corporation (Memryte), and Pain
Therapeutics, Inc. (Remoxy) and revenue of $1.6 million recognized in
connection with our assignment of certain intellectual property rights.
Research and development expenses were $7.0 million for the three months
ended September 30, 2005, compared with $6.6 million for the same period in
2004. The increase in the three months ended September 30, 2005 was primarily
attributable to the higher development expenses for SABER-Bupivacaine, DURIN-
Leuprolide and certain other product candidates, partially offset by lower
development expenses for CHRONOGESIC.
Selling, general and administrative expenses were $2.7 million for the
three months ended September 30, 2005, compared with $2.3 million for the same
period in 2004. The increase in the three months ended September 30, 2005 was
primarily due to higher external costs to support the operation of our
business and to comply with the Sarbanes-Oxley Act.
Net other expense was $1.0 million for the three months ended
September 30, 2005, compared with $796,000 for the same period in 2004. The
increase in net other expense in the three months ended September 30, 2005 was
primarily due to approximately $403,000 of non-cash debt conversion expense in
connection with the early conversion of a portion of our outstanding 6.25%
Convertible Subordinated Notes due 2008.
During the third quarter of 2005, we exchanged and cancelled approximately
$2.7 million in principal amount of our 6.25% Convertible Subordinated Notes
through conversions into our common stock. As of September 30, 2005, the
remaining principal balance of our 6.25% Convertible Subordinated Notes due
2008 was $57.3 million.
At September 30, 2005, DURECT had cash and investments of $59.2 million,
including $2.1 million in restricted investments, compared with cash and
investments of $61.8 million at December 31, 2004. We anticipate that our
December 31, 2005 cash and investments balance to be in the range of $48.0
million to $50.0 million.
About DURECT Corporation
DURECT Corporation is an emerging specialty pharmaceutical company focused
on the development of pharmaceutical systems based on its proprietary drug
delivery platform technologies that treat chronic or episodic diseases and
enable biotechnology products. These platform technologies include the
SABER(TM) Delivery System (a patented and versatile depot injectable useful
for protein and small molecule delivery), the ORADUR(TM) sustained release
oral gel-cap technology (an oral sustained release technology with several
potential abuse deterrent properties), the DURIN(TM) Biodegradable Implant
(drug-loaded implant system), the TRANSDUR(TM) transdermal technology and the
MICRODUR(TM) Biodegradable Microparticulates (microspheres injectable system).
DURECT also collaborates with pharmaceutical companies to develop and
commercialize proprietary and enhanced pharmaceutical products based on its
technologies. DURECT has five disclosed on-going development programs of which
four are in collaboration with pharmaceutical partners. Additional information
about DURECT is available at www.www.durect.com.
NOTE: SABER(TM), ORADUR(TM), DURIN(TM), TRANSDUR(TM), CHRONOGESIC(R) and
MICRODUR(TM) are trademarks of DURECT Corporation. Other referenced trademarks
belong to their respective owners.
DURECT Forward-Looking Statement
The statements in this press release regarding DURECT’s projected
financial results and DURECT’s and its collaborative partners’ products in
development, anticipated product benefits, and clinical trial results and
plans are forward-looking statements involving risks and uncertainties that
can cause actual results to differ materially from those in such forward-
looking statements. Potential risks and uncertainties include, but are not
limited to, DURECT’s (and that of its third-party collaborators’, where
applicable) abilities to successfully enroll and complete clinical trials,
complete the design, development, and manufacturing process development of the
product candidate, obtain product and manufacturing approvals from regulatory
agencies and manufacture and commercialize the product candidate, as well as
marketplace acceptance of the product candidate. Further information regarding
these and other risks is included in DURECT’s Quarterly Report on Form 10-Q
for the quarter ended September 30, 2005 filed with the SEC on October 13,
2005 under the heading “Factors that may affect future results.”
DURECT CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) Three months ended Nine months ended September 30, September 30, 2005 2004 2005 2004 (unaudited) (unaudited) (unaudited) (unaudited) Product revenue, net $1,653 $1,776 $5,299 $4,901 Revenue from sale of intellectual property rights 1,600 -- 1,600 -- Collaborative research and development and other revenue 5,369 1,589 15,896 4,929 Total revenues 8,622 3,365 22,795 9,830 Operating expenses: Cost of revenues 573 685 1,933 2,117 Research and development 6,964 6,571 21,195 18,020 Selling, general and administrative 2,699 2,262 8,015 6,825 Amortization of intangible assets 303 303 909 946 Stock-based compensation(1) 60 8 453 178 Total operating expenses 10,599 9,829 32,505 28,086 Loss from operations (1,977) (6,464) (9,710) (18,256) Other income (expense): Interest and other income 467 326 1,359 919 Interest expense (1,095) (1,122) (3,329) (3,346) Debt conversion expense (403) -- (403) -- Net other income (expense) (1,031) (796) (2,373) (2,427) Loss before income taxes (3,008) (7,260) (12,083) (20,683) Income tax provision 4 -- 4 -- Net loss $(3,012) $(7,260) $(12,087) $(20,683) Net loss per share, basic and diluted $(0.06) $(0.14) $(0.23) $(0.40) Shares used in computing basic and diluted net loss per share 52,786 51,670 52,240 51,397 (1) Stock-based compensation related to the following: Cost of revenues $-- $-- $ -- $1 Research and development 60 3 106 156 Selling, general and administrative -- 5 347 21 $60 $8 $453 $178 DURECT CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) September 30, December 31, 2005 2004 (1) Assets Current assets: Cash and cash equivalents, short term investments and restricted investments $50,044 $41,797 Accounts receivable 5,770 2,481 Inventories 2,124 1,929 Prepaid expenses and other current assets 1,852 1,364 Total current assets 59,790 47,571 Property and equipment, net 7,263 7,112 Goodwill 6,399 6,399 Intangible assets, net 835 1,745 Long-term investments and restricted investments 9,196 20,016 Other non-current assets 2,061 2,625 Total assets $85,544 $85,468 Liabilities and stockholders' equity Current liabilities: Accounts payable, accrued liabilities and deferred revenue $9,457 $5,006 Long-term obligations, current portion 294 483 Total current liabilities 9,751 5,489 Long-term obligations, noncurrent portion 64,912 61,589 Stockholders' equity 10,881 18,390 Total liabilities and stockholders' equity $85,544 $85,468 (1) Derived from audited financial statements.
SOURCE DURECT Corporation
CONTACT: Schond L. Greenway, Executive Director, Investor Relations and
Strategic Planning of DURECT Corporation, +1-408-777-1417